Thursday, June 23, 2016

BRIEF-Apellis announces results from Phase 1 complement C3 inhibitor trials

* Apellis Announces Positive Results From Phase 1 clinical

Trials Of Apl 2, a C3 complement inhibitor

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)